Colorectal Cancer Clinical Trial
Official title:
Measuring the Incidence of Colorectal Cancer in Young Endurance Athletes
The purpose of this study is to determine the frequency of colorectal cancer in male and female endurance athletes between the ages of 35 and 50.
Status | Recruiting |
Enrollment | 100 |
Est. completion date | August 31, 2025 |
Est. primary completion date | August 31, 2025 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 35 Years to 50 Years |
Eligibility | Inclusion Criteria: - Adult males and females 35-50 years of age - Male and female self-reported endurance athletes, defined by at least one of the following: - Run at least two races of 50 miles or more - Run 5 races of 26.2 miles or more - Ability to complete testing in the protocol and make study visits - Able and willing to consent to protocol Exclusion Criteria: - Known or suspected history of inflammatory bowel disease, familial adenomatous polyposis (FAP), or Lynch Syndrome - Concomitant illness that would prevent adequate patient assessment or in the investigators' opinion pose an added risk for study participants. - Anticipated poor compliance - Prisoners or subjects who are involuntarily incarcerated - Persons with decisional incapacity/cognitive impairment - Any history or evidence of severe illness or any other condition that would make the patient, in the opinion of the investigator unsuitable for the study - Subject is involved with a worker's compensation, personal injury, or other legal matters related to their health - Subject is enrolled in a separate interventional clinical trial |
Country | Name | City | State |
---|---|---|---|
United States | Inova Schar Cancer Institute | Fairfax | Virginia |
Lead Sponsor | Collaborator |
---|---|
Inova Health Care Services |
United States,
Baska RS, Moses FM, Graeber G, Kearney G. Gastrointestinal bleeding during an ultramarathon. Dig Dis Sci. 1990 Feb;35(2):276-9. doi: 10.1007/BF01536777. — View Citation
Blokzijl F, de Ligt J, Jager M, Sasselli V, Roerink S, Sasaki N, Huch M, Boymans S, Kuijk E, Prins P, Nijman IJ, Martincorena I, Mokry M, Wiegerinck CL, Middendorp S, Sato T, Schwank G, Nieuwenhuis EE, Verstegen MM, van der Laan LJ, de Jonge J, IJzermans JN, Vries RG, van de Wetering M, Stratton MR, Clevers H, Cuppen E, van Boxtel R. Tissue-specific mutation accumulation in human adult stem cells during life. Nature. 2016 Oct 13;538(7624):260-264. doi: 10.1038/nature19768. Epub 2016 Oct 3. — View Citation
Casey E, Mistry DJ, MacKnight JM. Training room management of medical conditions: sports gastroenterology. Clin Sports Med. 2005 Jul;24(3):525-40, viii. doi: 10.1016/j.csm.2005.05.002. — View Citation
Clausen JP. Effect of physical training on cardiovascular adjustments to exercise in man. Physiol Rev. 1977 Oct;57(4):779-815. doi: 10.1152/physrev.1977.57.4.779. No abstract available. — View Citation
Cong YJ, Gan Y, Sun HL, Deng J, Cao SY, Xu X, Lu ZX. Association of sedentary behaviour with colon and rectal cancer: a meta-analysis of observational studies. Br J Cancer. 2014 Feb 4;110(3):817-26. doi: 10.1038/bjc.2013.709. Epub 2013 Nov 21. — View Citation
de Oliveira EP, Burini RC. The impact of physical exercise on the gastrointestinal tract. Curr Opin Clin Nutr Metab Care. 2009 Sep;12(5):533-8. doi: 10.1097/MCO.0b013e32832e6776. — View Citation
Heer M, Repond F, Hany A, Sulser H, Kehl O, Jager K. Acute ischaemic colitis in a female long distance runner. Gut. 1987 Jul;28(7):896-9. doi: 10.1136/gut.28.7.896. — View Citation
Hemmasi G, Sohrabi M, Zamani F, Ajdarkosh H, Rakhshani N, Khoonsari M, Ameli M, Hatami K. Prevalence of colorectal adenoma in an average-risk population aged 40-50 versus 50-60 years. Eur J Cancer Prev. 2015 Sep;24(5):386-90. doi: 10.1097/CEJ.0000000000000097. — View Citation
Kehl O, Jager K, Munch R, Buhler H, Segantini P, Bollinger A, Ammann R. [Mesenterial anemia as a cause of jogging anemia?]. Schweiz Med Wochenschr. 1986 Jul 19;116(29):974-6. German. — View Citation
Meyer JE, Narang T, Schnoll-Sussman FH, Pochapin MB, Christos PJ, Sherr DL. Increasing incidence of rectal cancer in patients aged younger than 40 years: an analysis of the surveillance, epidemiology, and end results database. Cancer. 2010 Sep 15;116(18): — View Citation
Nieman DC, Konrad M, Henson DA, Kennerly K, Shanely RA, Wallner-Liebmann SJ. Variance in the acute inflammatory response to prolonged cycling is linked to exercise intensity. J Interferon Cytokine Res. 2012 Jan;32(1):12-7. doi: 10.1089/jir.2011.0038. Epub — View Citation
Porter AM. Do some marathon runners bleed into the gut? Br Med J (Clin Res Ed). 1983 Nov 12;287(6403):1427. doi: 10.1136/bmj.287.6403.1427. No abstract available. — View Citation
Sanchez LD, Tracy JA, Berkoff D, Pedrosa I. Ischemic colitis in marathon runners: a case-based review. J Emerg Med. 2006 Apr;30(3):321-6. doi: 10.1016/j.jemermed.2005.05.021. — View Citation
Scott JP, Sale C, Greeves JP, Casey A, Dutton J, Fraser WD. Effect of exercise intensity on the cytokine response to an acute bout of running. Med Sci Sports Exerc. 2011 Dec;43(12):2297-306. doi: 10.1249/MSS.0b013e31822113a9. — View Citation
Siegel RL, Fedewa SA, Anderson WF, Miller KD, Ma J, Rosenberg PS, Jemal A. Colorectal Cancer Incidence Patterns in the United States, 1974-2013. J Natl Cancer Inst. 2017 Aug 1;109(8):djw322. doi: 10.1093/jnci/djw322. — View Citation
Steiner P. When suspected 'runner's colitis' in a marathon runner turns out to be cancer-and in the end leads to a new personal best marathon time. Br J Sports Med. 2020 Mar;54(5):311-312. doi: 10.1136/bjsports-2019-100675. Epub 2019 Aug 2. No abstract av — View Citation
Thomas RJ, Kenfield SA, Jimenez A. Exercise-induced biochemical changes and their potential influence on cancer: a scientific review. Br J Sports Med. 2017 Apr;51(8):640-644. doi: 10.1136/bjsports-2016-096343. Epub 2016 Dec 19. — View Citation
Tomasetti C, Li L, Vogelstein B. Stem cell divisions, somatic mutations, cancer etiology, and cancer prevention. Science. 2017 Mar 24;355(6331):1330-1334. doi: 10.1126/science.aaf9011. — View Citation
Xu G, Lin W, McAinch AJ, Yan X, Weng X. Identification of Urinary Biomarkers for Exercise-Induced Immunosuppression by iTRAQ Proteomics. Biomed Res Int. 2020 Jan 23;2020:3030793. doi: 10.1155/2020/3030793. eCollection 2020. — View Citation
* Note: There are 19 references in all — Click here to view all references
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | rate of young endurance athletes that have adenomatous polyps | The rate of adenomatous polyps and colorectal cancer will be estimated with their 95% confidence intervals using the exact binomial method | 36 months | |
Primary | rate of young endurance athletes that have colorectal cancer on screening colonoscopies. | The rate of adenomatous polyps and colorectal cancer will be estimated with their 95% confidence intervals using the exact binomial method | 36 months | |
Secondary | comparison of the rate of young endurance athletes that have adenomatous polyps with that of the historical controls (those in the average risk group) | Fisher's Exact test will be used to compare the rates of adenomatous polyps and colorectal cancer between the young endurance athletes and that of the historical controls. | 36 months | |
Secondary | Comparison of the rate of young endurance athletes that have colorectal cancer on screening colonoscopies with that of the historical controls (those in the average risk group). | Fisher's Exact test will be used to compare the rates of adenomatous polyps and colorectal cancer between the young endurance athletes and that of the historical controls. | 36 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
Active, not recruiting |
NCT05551052 -
CRC Detection Reliable Assessment With Blood
|
||
Completed |
NCT00098787 -
Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer
|
Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT05425940 -
Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer
|
Phase 3 | |
Suspended |
NCT04595604 -
Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery.
|
N/A | |
Completed |
NCT03414125 -
Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening
|
N/A | |
Completed |
NCT02963831 -
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
Terminated |
NCT01847599 -
Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib
|
N/A | |
Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
Recruiting |
NCT03874026 -
Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03167125 -
Participatory Research to Advance Colon Cancer Prevention
|
N/A | |
Completed |
NCT03181334 -
The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation
|
N/A | |
Recruiting |
NCT04258137 -
Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study
|
N/A | |
Recruiting |
NCT05568420 -
A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
|
||
Recruiting |
NCT02972541 -
Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer
|
N/A | |
Completed |
NCT02876224 -
Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors
|
Phase 1 | |
Completed |
NCT01943500 -
Collection of Blood Specimens for Circulating Tumor Cell Analysis
|
N/A |